피엔케이피부임상연구센타
Financials
Valuation Metrics
피엔케이피부임상연구센타's Market Cap is ₩525B. At end of 2025 it was ₩768B. Ranked #1742 of 2,421 in KR market (top 72%), #1057 of 1,640 on KOSDAQ (top 64%), #184 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 52.49B KRW | KR#1,742/2,421 Sec#184/231 |
| Revenue | 23.67B KRW | KR#2,103/2,421 Sec#149/231 |
| Net Income | 3.63B KRW | KR#1,310/2,421 Sec#92/231 |
| Total Assets | 88.37B KRW | KR#1,876/2,421 Sec#151/231 |
| Net Assets | 82.18B KRW | KR#1,565/2,421 Sec#126/231 |
| Employees | 104 | KR#1,613/2,421 Sec#126/231 |
| Value | ||
| P/E | 14.44x | KR#1,025/2,421 Sec#59/231 |
| P/B | 0.64x | KR#1,037/2,421 Sec#54/231 |
| PEG | 0.38x | KR#660/2,421 Sec#42/231 |
| P/S | 2.22x | KR#1,866/2,421 Sec#107/231 |
| FCF Yield | 9.86% | KR#614/2,421 Sec#26/231 |
| Profitability | ||
| ROE | 4.42% | KR#1,168/2,421 Sec#81/231 |
| ROA | 4.11% | KR#844/2,421 Sec#69/231 |
| Op. Margin | 15.52% | KR#280/2,421 Sec#27/231 |
| Revenue Growth | 8.60% | KR#975/2,421 Sec#95/231 |
| Earnings Growth | 38.37% | KR#599/2,421 Sec#39/231 |
| Financial Health | ||
| Debt Ratio | 7.53% | KR#80/2,421 Sec#16/231 |
| FCF | 5.18B KRW | KR#900/2,421 Sec#63/231 |
| Cash | 2.75B KRW | KR#2,186/2,421 Sec#208/231 |
| Current Ratio | 7.75x | KR#152/2,421 Sec#32/231 |
| Dividend | ||
| Div. Yield | 2.84% | KR#675/2,421 Sec#35/231 |
| Div. Growth | 25.00% | KR#391/2,421 Sec#20/231 |
| Performance | ||
| 1Y Return | -40.00% | KR#1,828/2,421 Sec#152/231 |
| 1M Return | -10.86% | KR#2,131/2,421 Sec#177/231 |
| From 52W High | -43.58% | KR#1,087/2,421 Sec#77/231 |
| 1Y MDD | -47.25% | KR#868/2,421 Sec#73/231 |
| Trading | ||
| Volume | 19,753 shares | KR#1,593/2,421 Sec#156/231 |
| Trading Value | 34.6M KRW | KR#1,969/2,421 Sec#202/231 |
| Foreign Own. | 1.61% | KR#1,788/2,421 Sec#174/231 |
| Per Share | ||
| EPS | 121 KRW | KR#1,400/2,421 Sec#93/231 |
| BPS | 2,738 KRW | KR#1,916/2,421 Sec#148/231 |
Company Info
PNK Skin Clinical Research Center was established in 2010 as Korea's first joint human application testing institution by Daebong LS and a medical college research institute, listing on KOSDAQ in 2020. The company conducts safety and efficacy verification tests for products like cosmetics and health functional foods, while also providing technology and information for new ingredient development and functional cosmetic testing. It leads the market with new protocol development and global-level data reliability, earning technological recognition through a strategic technology cooperation MOU with BASF in 2019.